Atsuko Y Higashi1, Bruce J Aronow2, Gregory R Dressler3. 1. Department of Pathology, University of Michigan, Ann Arbor, Michigan; and. 2. Department of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Department of Pathology, University of Michigan, Ann Arbor, Michigan; and dressler@umich.edu.
Abstract
BACKGROUND: Renal interstitial fibrosis results from activation and proliferation of fibroblasts to myofibroblasts, secretion and accumulation of extracellular matrix, and displacement of normal renal tubules. In contrast to chronic renal disease, acute injury may be repaired, a process that includes a decrease in the number of myofibroblasts in the interstitium and degradation of the accumulated extracellular matrix, leaving little evidence of prior injury. METHODS: To investigate whether activated fibroblasts demonstrate changes in gene expression that correspond with regression after acute injury but are not observed in chronic models of fibrosis, we used microarrays to analyze gene expression patterns among fibroblast populations at different stages of injury or repair. We then mined the data for signaling pathways in fibroblasts corresponding to the acute proliferative, regression, and chronic phases of renal injury. RESULTS: We identified multiple gene clusters with changes that correlate with the three phases of renal injury, including changes in levels of receptors for the antifibrotic factor PGE2. In adult renal fibroblast cultures, PGE2 was able to upregulate many genes that are suppressed by the profibrotic cytokine TGF-β, whereas many PGE2-downregulated genes were activated by TGF-β. High levels of TGF-β suppressed expression of a subset of PG receptors in fibroblast cultures, making these cells resistant to any effects of PGE2. CONCLUSIONS: Inherent gene expression changes in activated fibroblasts accompany the transition from AKI to repair and regeneration. In chronic models, however, activated fibroblasts are resistant to the antifibrotic effects of PGE2 due to suppression of a subset of PGE receptors.
BACKGROUND:Renal interstitial fibrosis results from activation and proliferation of fibroblasts to myofibroblasts, secretion and accumulation of extracellular matrix, and displacement of normal renal tubules. In contrast to chronic renal disease, acute injury may be repaired, a process that includes a decrease in the number of myofibroblasts in the interstitium and degradation of the accumulated extracellular matrix, leaving little evidence of prior injury. METHODS: To investigate whether activated fibroblasts demonstrate changes in gene expression that correspond with regression after acute injury but are not observed in chronic models of fibrosis, we used microarrays to analyze gene expression patterns among fibroblast populations at different stages of injury or repair. We then mined the data for signaling pathways in fibroblasts corresponding to the acute proliferative, regression, and chronic phases of renal injury. RESULTS: We identified multiple gene clusters with changes that correlate with the three phases of renal injury, including changes in levels of receptors for the antifibrotic factor PGE2. In adult renal fibroblast cultures, PGE2 was able to upregulate many genes that are suppressed by the profibrotic cytokine TGF-β, whereas many PGE2-downregulated genes were activated by TGF-β. High levels of TGF-β suppressed expression of a subset of PG receptors in fibroblast cultures, making these cells resistant to any effects of PGE2. CONCLUSIONS: Inherent gene expression changes in activated fibroblasts accompany the transition from AKI to repair and regeneration. In chronic models, however, activated fibroblasts are resistant to the antifibrotic effects of PGE2 due to suppression of a subset of PGE receptors.
Authors: Irina A Leaf; Shunsaku Nakagawa; Bryce G Johnson; Jin Joo Cha; Kristen Mittelsteadt; Kevin M Guckian; Ivan G Gomez; William A Altemeier; Jeremy S Duffield Journal: J Clin Invest Date: 2016-11-21 Impact factor: 14.808
Authors: Jill E Kolodsick; Marc Peters-Golden; Jose Larios; Galen B Toews; Victor J Thannickal; Bethany B Moore Journal: Am J Respir Cell Mol Biol Date: 2003-05-08 Impact factor: 6.914
Authors: Miguel Moyses Neto; Roberto S Costa; Rildo A Volpini; Tânia M P Garcia; Fernanda F Rodrigues; Terezila M Coimbra Journal: Clin Transplant Date: 2004-04 Impact factor: 2.863
Authors: Jing Liu; Sanjeev Kumar; Egor Dolzhenko; Gregory F Alvarado; Jinjin Guo; Can Lu; Yibu Chen; Meng Li; Mark C Dessing; Riana K Parvez; Pietro E Cippà; A Michaela Krautzberger; Gohar Saribekyan; Andrew D Smith; Andrew P McMahon Journal: JCI Insight Date: 2017-09-21
Authors: Tomohito Doke; Amin Abedini; Daniel L Aldridge; Ya-Wen Yang; Jihwan Park; Christina M Hernandez; Michael S Balzer; Rojesh Shrestra; Gaia Coppock; Juan M Inclan Rico; Seung Yub Han; Junhyong Kim; Sheng Xin; Adrian M Piliponsky; Marco Angelozzi; Veronique Lefebvre; Mark C Siracusa; Christopher A Hunter; Katalin Susztak Journal: Nat Immunol Date: 2022-05-12 Impact factor: 31.250